No Significant Difference between Tocilizumab and Placebo in Severe COVID-19 Pneumonia Patients

In this randomized trial involving hospitalized patients with severe COVID-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. In this... read more

The Effect of Early Sedation With Dexmedetomidine on Body Temperature in Critically Ill Patients

Previous case series reported an association between dexmedetomidine use and hyperthermia. Temperature data have not been systematically reported in previous randomized controlled trials evaluating dexmedetomidine. Our... read more

COVID-19 Awake Proning – All Hype?

In this prospective meta-analysis of observational studies of patients with acute hypoxemic respiratory failure due to COVID-19, APP did not result in lower intubation or mortality rates, despite reported improvements in... read more

Supraclavicular Subclavian Vein Catheterization – The Forgotten Central Line

While the supraclavicular approach to the subclavian vein has been described since 1965, it is generally employed much less often than the "traditional" infraclavicular approach. Although randomized trials are lacking, the... read more

Nebulised heparin for patients with or at risk of ARDS

In patients with or at risk of acute respiratory distress syndrome (ARDS), nebulised heparin did not improve self-reported performance of daily physical activities, but was well tolerated and exploratory outcomes suggest... read more

Association between perioperative fluid administration and postoperative outcomes

Irrespectively to the amount of perioperative fluid administered, goal-directed therapy (GDT) strategy reduces postoperative complications, but not perioperative mortality. The metanalysis included 21 RCTs enrolling 2,729... read more

Targeting MAP in Sepsis

What’s your target mean arterial pressure (MAP) for patients with sepsis? Do you believe in the magic number of 65? What about those patients with chronic hypertension? What about when there is no evidence of end organ... read more

High-dose Vitamin C in Critically Ill COVID-19 Patients

This pilot trial showed that high-dose intravenous vitamin C (HDIVC) failed to improve IMVFD28, but might show a potential signal of benefit in oxygenation for critically ill patients with COVID-19 improving PaO2/FiO2 even... read more

Colchicine, the only effective oral medication for treating non-hospitalized COVID-19 patients

The Montreal Heart Institute announced COLCORONA clinical trial has provided clinically persuasive results of colchicine's efficacy to treat COVID-19. The study results show that colchicine reduces the risk of death or... read more

Full-dose blood thinners decreased need for life support and improved outcomes in COVID-19 patients

Full dose anticoagulation (blood thinner) treatments given to patients hospitalized for COVID-19 reduced the requirement of vital organ support in a large clinical trial conducted worldwide. With large numbers of COVID-19... read more

Tocilizumorelikeit? The latest data on Tocilizumab

Our hats were then blown away when the REMAP-CAP team and the UK government fired an evidence-based carpet bomb in our direction. We saw a trial press release, a preprint article, an alert letter from the MHRA/DHSC, national... read more

Harnessing a Pioneering Cell Therapy Treatment for COVID-19 Patients with ARF

A world-leading UK-wide trial supported by NIHR is offering a pioneering cell therapy treatment for patients with acute respiratory failure (ARF) caused by COVID-19. The groundbreaking study, led by experts at Queen's... read more

Adjuvant therapeutic plasma exchange in septic shock

The hallmark of sepsis is a pathological host response to an infection that may lead to organ dysfunction, shock and high mortality. Besides numerous circulating mediators initiating inflammation, vascular barrier breakdown... read more

Effect of Out-of-Hospital Sodium Nitrite on Survival to Hospital Admission After Cardiac Arrest

Among patients with out-of-hospital cardiac arrest, administration of sodium nitrite, compared with placebo, did not significantly improve survival to hospital admission. These findings do not support the use of sodium nitrite... read more

COVID-19 Blood Plasma Trial Finds No Benefit in Severely Ill Patients

An international trial testing convalescent blood plasma on COVID-19 patients with moderate and severe illness has halted enrolment of severely ill COVID-19 patients requiring intensive care after it found no benefit. The... read more

Mortality Among LVAD Recipients Ineligible for Clinical Trials

These findings suggest that while treatment for patients who are ineligible for left ventricular assist device (LVAD) trial inclusion should be weighed against medical management, more consideration could be given to designing... read more

Cost-effectiveness of Adrenaline for Out-of-Hospital Cardiac Arrest

Adrenaline was not cost-effective when only directly related costs and consequences are considered. However, incorporating the indirect economic effects associated with transplanted organs substantially alters cost-effectiveness,... read more

Allergic Reactions to COVID-19 Vaccine

To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing... read more

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The mRNA-1273 vaccine showed 94.1% efficacy at preventing COVID-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. The trial enrolled 30,420 volunteers... read more

The Evolving Armamentarium of COVID-19 Therapeutics

Multiple repositories have been created for the vast scientific outpouring of COVID-19 research. The NIH regularly updates its treatment guidelines, which will be the primary reference for this review. To cut to the... read more

Pfizer and BioNTech Speed Up Timeline for COVID-19 Vaccine

Pfizer and its partner BioNTech plan to offer their Covid-19 vaccine to any clinical trial volunteer who received placebo by March 1, several months earlier than initially planned. The decision represents the conclusion... read more

Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19

Primary outcome in the RECOVERY trial and in the WHO REACT meta-analysis was 28-day mortality. Assessing 28-day mortality may not be the optimal outcome in a trial. Since patients with severe COVID-19 often require prolonged... read more